Vagus Nerve and Its Role in Dysautonomia
The persistent presence of symptoms such as heart rate abnormalities, digestive issues, sleep disturbances, fatigue, pain and cognitive impairment are prevalent in a condition known as dysautonomia. This disorder is characterised by the malfunction of the autonomic nervous system (ANS), resulting in reduced vagal tone, often caused by persistent inflammation of the vagus nerve due to psychological stress, infections, medications and environmental toxicity. The vagus nerve is responsible for the parasympathetic response of the nervous system, regulating functions such as heart rate, digestion, immune response, and metabolic rate, all of which can become impaired and contribute to the aforementioned symptoms, and its impairment can cause:
Heart Rate Variability (HRV) dysregulation
Vagus nerve impairment in dysautonomia leads to irregular control of heart rate and blood pressure due to imbalance toward sympathetic dominance and a prolonged stress response. The vagus nerve impairment is measured by decreased heart rate variability (HRV) resulting from the inability of its efferent fibres to effectively send signals from the brain to the heart, leading to decreased parasympathetic control which can lead to erratic heart rhythms (tachycardia, bradycardia, including orthostatic hypotension) and alter respiratory patterns (abnormal breathing rates, sleep apnea).
Altered Stress Responses
In dysautonomia, a compromised vagal nerve means less effective management of stress, which can lead to long-term oxidative stress and immune system dysfunction. Impairment of the Vagus Nerve disturbs the functioning of the hypothalamic-pituitary-adrenal (HPA) axis, resulting in prolonged stress reactions and symptoms of persistent anxiety, heart palpitations and chronic inflammation, due to reduced resilience for cortisol.
Inflammatory Response Imbalance
The modulation of the immune system's inflammatory response by the vagus nerve can be impeded in dysautonomia. The vagus nerve transmits signals related to the body's inflammatory response, through the cholinergic anti-inflammatory pathway. During dysautonomia, the body's immune system releases various cytokines and inflammatory molecules in an uncontrolled way. Such immune dysregulation, from the impaired function of the vagus nerve, contributes to symptoms like fatigue and brain fog, pain and sleep disturbances and heart palpitations.
The Brain-Gut Axis
A reduction in vagal tone, indicative of dysautonomia, has been observed in conditions like Irritable Bowel Syndrome (IBS) and Inflammatory Bowel Disease (IBD), underscoring the vagus nerve's significant role in the gut-brain axis. This nerve is crucial in the neuroendocrine-immune axis, connecting the central nervous system (CNS) with the gut. Dysautonomia, characterised by dysfunction of the autonomic nervous system, may impair the vagus nerve's functionality. This impariment can affect the regulation of neurotransmitters linked to physiological and psychological health. As a result, affected the vagus nerve can lead to symptoms such as fatigue, depression, gastrointestinal problems, heightened stress, depression, and even cardiovascular problems.
Improved heart rate variability (HRV)
Nurosym boosts vagal tone, effectively alleviating symptoms of dysautonomia as evidenced by improvements in Heart Rate Variability (HRV). An increased HRV observed during Nurosym sessions signifies enhanced parasympathetic activity, or the "rest and digest '' response. This enhancement is linked to anti-inflammatory effects, with decreased markers of oxidative stress and norepinephrine levels. Consequently, this leads to a reduction in irregular heart rhythms such as tachycardia and bradycardia, and helps in stabilising blood pressure. Additionally, Nurosym's influence on the vagal tone can positively modify respiratory patterns and reduce pain.
Stress Response Regulation
Nurosym can modulate the stress response by activating the parasympathetic nervous system. This activation can help in regulating the hypothalamic-pituitary-adrenal (HPA) axis, a key neuroendocrine system involving the hypothalamus, pituitary gland, and adrenal glands, which in turn reduce the prolonged stress reactions. By calming the stress response, Nurosym may reduce dysautonomia symptoms like persistent anxiety, pain, heart palpitations, and chronic inflammation.
Anti-inflammatory Effects
Nurosym demonstrated a reduction in the levels of anti-autonomic autoantibodies (a1-AR and b1-AR), components in the pathophysiology of POTS. These autoantibodies adversely affect the nervous system by targeting adrenergic receptors. Through the cholinergic anti-inflammatory pathway, Nurosym was proven to regulate the immune system’s response, which can be beneficial in Dysautonomia patients. By stimulating the vagus nerve, Nurosym reduces the uncontrolled release of cytokines and inflammatory molecules, thereby alleviating dysautonomia symptoms related to systemic inflammation and improved function of the body's organs like heart, brain, and gastrointestinal system.
The Brain-Gut Axis
The stimulation provided by Nurosym improves vagal tone, which is crucial in the gut-brain axis, a critical communication pathway between the gastrointestinal system and the central nervous system. This improvement in vagal tone may lead to relief from symptoms commonly associated with dysautonomia, such as digestive tract problems, chronic fatigue, irregular heart rates, acute diarrhoea episodes, fainting, and sleep disturbances. This may also be beneficial in conditions like Type 2 Diabetes, Irritable Bowel Syndrome (IBS), Inflammatory Bowel Disease (IBD).
Nurosym Research-Based Evidence
After two months of consistent Nurosym treatment, 79% of POTS patients reported a significant decrease in abnormal heart rates.
Nurosym research has further demonstrated a 40% reduction in heart rate change [Δ (heart rate)] with reduction in the levels of anti-autonomic autoantibodies (α-1AR and β-1AR), during this period in POTS patients.

(Fig). Effect of Nurosym neuromodulation vs. Placebo control on the postural change in heart rate [Δ (heart rate)] at 2 months (Parasym Clinical Trials, 2023).
In the Parasym clinical trial, a 29% reduction in autoantibodies was observed after Nurosym therapy compared to the placebo. This decline showed a correlation with improved cardiovascular function and diminished cardiac damage in POTS.

Fig (A, B). Comparison of antiautonomic autoantibody activity between Nurosym neuromodulation and Placebo control at 3 months change. (A) β1-adrenergic (β-1AR) autoantibody activity. (B) α1-adrenergic receptor (α-1AR) autoantibody activity. P < 0.05. An=antibody. (Parasym Clinical Trials, 2023).
Nurosym demonstrated an increase in heart rate variability (HRV) by 61%. Given that dysautonomia precedes the onset of autoimmune disease, especially in younger people, paying close attention to vagus nerve activation may have a positive impact on reducing the risk of further disease development.

(Fig A, B, C, D) In the autonomic function response, Nurosym Neuromodulation positively changed all HRV parameters (A: HF, B: RMSSD, C: pRR50, D: SDRR) (Parasym Clinical Trials, 2022).
Nurosym treatment has shown promising results in reducing coexisting symptoms of POTS, such as fatigue, depression and brain fog.
After 2 weeks of Nurosym neuromodulation therapy, patients experienced an average of 57% improvement in cognition related to symptoms of brain fog, fatigue as evidenced in clinical trials.
In clinical Nurosym trials patients after 10 days of neuromodulation therapy experienced on average 43% improved mood according to the Beck Depression Scale, 48% less fatigue and brain fog according to the fatigue Pichot scale.

(Fig). The Pichot fatigue scale scores during Nurosym therapy (D0: day 0, D5: day 5 and D10: day 10). Significant improvement in fatigue scores after Nurosym treatment was observed (D0 vs. D10, p<0.0001). (Parasym clinical trial, 2021).

(Fig). Evolution of the Beck depression scale scores during treatment (day 0, day 5 and day 10). The individual values and the median are shown. Non parametric Friedman statistics for paired comparisons were used and followed by post-hoc Dunn’s multiple comparisons test. (Parasym clinical trial, 2021).
Another Nurosym finding highlights 78% reduction in inflammation in IL-6 (and cytokines levels like IL-8, TNF-α). This reduction in inflammation is particularly pronounced in individuals with dysautonomia, demonstrating a more robust positive response to the treatment. The decreased inflammation is correlated with reduced oxidative stress, reduction in tissue damage and enhanced cardiac function.

(Fig A, B) In a three-month study employing the Nurosym device for heart failure patients, notable improvements (*P<0.05) were noted in inflammatory biomarkers: (A) Tumor Necrosis Factor (TNF)‐α exhibited a ~23% reduction, while (B) Interleukin (IL)‐8 showed a marked ~61.3% reduction. The investigation specifically targeted participants with elevated baseline inflammation levels (Parasym Clinical Trials, 2022).
In clinical trials with dysautonomia participants, assessments at baseline (Day 0), post-intervention (Day 10), and 1-month follow-up showed significant cognitive improvements: a 17% improvement in overall Fluid Cognition.

(Fig). The Fluid Cognition Score represents cognitive performance across several domains, including Pattern Comparison Processing Speed, Pattern Sequencing Memory, and List Sorting Working Memory. The study showed significant increases from baseline to post-intervention and follow-up (p < 0.01). Friedman’s test indicated a significant main effect of time (p = 0.001) across all composite cognitive scores (Parasym Clinical Trials, 2024).
Doctors about Nurosym
Patients about Nurosym
Jane
“I’ve struggled with Lyme disease, autonomic issues, EBV, pituitary problems including adrenal insufficiency, fatigue, insomnia and gastrointestinal issues. It was very serious, in and out of hospitals, I needed a wheelchair and was practically bed bound for several years. Many days I couldn’t even lift my head off the pillow due to my fatigue and Postural tachycardia syndrome (PoTS). I’ve seen so many doctors and taken so many different medications and supplements. With the Parasym I now have a tool I can use myself at home which doesn’t have the nasty side effects medications do. My PoTS, although still present, is much more manageable”
Connie
“It’s really amazing finding a product like this that you can use every day. A new tool in your health toolkit. I would recommend it to anyone having vagus nerve issues or symptoms, who is looking for something to help at home.”
Who is for it?
Nurosym proves to be an effective therapy for people struggling with the lasting effects of dysautonomia disorders such as POTS. Tailored for people with POTS and dysautonomia, conditions characterised by persistent symptoms, including fatigue, cognitive impairment and autonomic dysfunction. Nurosym stands out by direct stimulation of the nervous system, offering treatment of the causes of disease rather than symptomatic treatment compared to traditional pharmacological interventions.
Nurosym has demonstrated the ability not only to alleviate cardiovascular symptoms associated with POTS within 2 months of treatment, but also to improve mood and reduce sleep disturbances after just 5 days of use. This highlights the significant impact of Nurosym on improving cognitive and physiological functions in people with POTS and dysautonomia.
Protocol - How to Use
Based on research, the purpose of treating dysautonomia and postural orthostatic tachycardia syndrome (POTS) for a period of 2 months, it is recommended to use Nurosym regularly for 1 hour a day. Postural tachycardia should stop after this time, but it is recommended to use Nurosym to prevent recurrence of the disease and to inhibit inflammatory processes in the body.
During Nurosym treatment, it is advisable to monitor potassium levels and maintain them within the normal range, which can further enhance the positive impact of the treatment. Nurosym proves to be safe for patients, including those with an implanted cardioverter-defibrillator (ICD), sinus node dysfunction, AV block, intraventricular conduction delay, and individuals post-myocardial infarction. In such cases, it is refrained from instantly discontinuing drug treatment. However, Nurosym may alleviate undesirable symptoms of drug treatment originating from the central nervous system and gastrointestinal tract and additionally strengthen the effect of treatment.
How often
Nurosym is recommended for use twice daily based on clinical research and patient feedback. This regimen ensures optimal energy balancing and nervous system calming.
How long
Users should allocate 30 minutes in the morning and 60 minutes before sleep for Nurosym therapy sessions. Consistency in application is key to achieving desired results.
Results
Positive outcomes from Nurosym therapy may become noticeable within a relatively short timeframe. Many individuals report improvements within days of starting treatment.